Skip to main content

Table 1 Patient characteristics

From: Evaluation of intravenous voriconazole in patients with compromised renal function

Parameter

Voriconazole

Caspofungin

Fluconazole

    p-value for overall difference

n (%)

19 (14.8)

55 (43.0)

54 (42.2)

 

Age, Mean (SD)

61.7 (13.9)

63.9 (13.9)

63.7 (14.7)

0.83

Male, n (%)

10 (52.6)

34 (61.8)

20 (37.0)

0.03

White, n (%)

17 (89.5)

43 (78.2)

49 (90.7)

0.63

Length of treatment (days)

    

 Mean (SD)

8.1 (6.3)

8.6 (5.3)

9.8 (9.8)

0.62

 Median (IQR)

6.0 (4–12)

7.0 (5–11)

8.0 (5–11)

0.53

 Min, Max

2, 29

2, 27

2, 74

NS

Comorbidities: Diabetes mellitus, hypertension or nephropathy, n (%)

11 (57.9)

46 (83.6)

43 (79.6)

0.06

Underlying condition, n (%)

   

0.001

 Cancer

12 (63)*

7 (13)

13 (24)

 

 HIV

0

0

1

 

 ICU

15 (79)

31 (56)

26 (48)

 

 Immunosuppression**

12 (63)

3 (5)

12 (22)

 

 More than 1 underlying condition

12 (63)

9 (16)

16 (30)

 

Concomitant nephrotoxic agent, n (%)

14 (73.7)

31 (56.4)

27 (50.0)

0.20

Underlying fungal disease, n (%)*

   

0.002

Candida spp.

5 (55.6)

43 (93.5)

39 (92.9)

 

Aspergillus spp.

4 (44.4)

3 (6.5)

3 (7.1)

 

Indication for antifungal therapy, n (%)

   

NS

 Prophylaxis

10 (53)

8 (15)

5 (9)

 

 Empiric

0

1 (2)

5 (9)

 

 Presumed or Confirmed

9 (47)

46 (84)

42 (78)

 
  1. *10 patients with AML were treated with voriconazole prophylaxis.
  2. **Chemotherapy, transplant rejection prevention or treatment, ≥ 1 mg/kg prednisone.
  3. Cases were included only when an Infectious Diseases consultant determined that the isolate represented an infection rather than colonization.